Screener
ImmunityBio, Inc. IBRX Reportable Segment — Total other expense, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense related to revenue interest liability | (13,871) | (13,534) |
| Change in fair value of derivative liabilities | 1,108 | 5,578 |
| Other expense, net | (5,917) | (41) |
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interests | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — total other expense, net?
- ImmunityBio, Inc. (IBRX) reported reportable segment — total other expense, net of -$563M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — total other expense, net changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — total other expense, net decreased by 759.9% year-over-year, from -$65.47M to -$563M.
- What does reportable segment — total other expense, net mean?
- The aggregate of all non-operating financial items, including interest, fair value adjustments, and other miscellaneous income or expenses. It provides a comprehensive view of the non-operating financial burden on the segment.
Ask your AI about ImmunityBio, Inc.'s reportable segment — total other expense, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude